Search

Your search keyword '"Lindberg, Morten"' showing total 150 results
Start Over Author "Lindberg, Morten"
150 results on '"Lindberg, Morten"'

4. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial

Author

Hofsø, Dag, Fatima, Farhat, Borgeraas, Heidi, Birkeland, Kåre Inge, Gulseth, Hanne Løvdal, Hertel, Jens Kristoffer, Johnson, Line Kristin, Lindberg, Morten, Nordstrand, Njord, Cvancarova Småstuen, Milada, Stefanovski, Darko, Svanevik, Marius, Gretland Valderhaug, Tone, Sandbu, Rune, and Hjelmesæth, Jøran

Published
2019
Full Text
View/download PDF

9. Single-centre, non-randomised clinical trial at a tertiary care centre to investigate 1-year changes in social experiences and biomarkers of well-being after bariatric surgery in individuals with severe obesity: protocol for the Bariatric Surgery and Social Experiences (BaSES) study

Author

Pfabigan, Daniela Melitta, primary, Hertel, Jens Kristoffer, additional, Svanevik, Marius, additional, Lindberg, Morten, additional, Sailer, Uta, additional, and Hjelmesæth, Jøran, additional

Published
2023
Full Text
View/download PDF

10. Single-centre, non-randomised clinical trial to investigate the effects of bariatric surgery on social experiences and biomarkers of well-being one year after surgery in individuals with severe obesity: a protocol for the Bariatric Surgery and Social Experiences (BaSES) study

Author

Pfabigan, Daniela M., primary, Hertel, Jens K., additional, Svanevik, Marius, additional, Lindberg, Morten, additional, Sailer, Uta, additional, and Hjelmesæth, Jøran, additional

Published
2022
Full Text
View/download PDF

21. Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis

Author

Seeberg, Kathrine Aglen, primary, Borgeraas, Heidi, additional, Hofsø, Dag, additional, Småstuen, Milada Cvancarova, additional, Kvan, Nils Petter, additional, Grimnes, John Olav, additional, Lindberg, Morten, additional, Fatima, Farhat, additional, Seeberg, Lars Thomas, additional, Sandbu, Rune, additional, Hjelmesæth, Jøran, additional, and Hertel, Jens Kristoffer, additional

Published
2022
Full Text
View/download PDF

23. Additional file 4 of Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms

Author

Bigseth, Therese Torgersen, Engh, John Abel, Egeland, Jens, Andersen, Eivind, Andreassen, Ole Andreas, Bang-Kittilsen, Gry, Falk, Ragnhild Sørum, Holmen, Tom Langerud, Lindberg, Morten, Mordal, Jon, Nielsen, Jimmi, Steen, Nils Eiel, Ueland, Thor, Vang, Torkel, and Fredriksen, Mats

Subjects
surgical procedures, operative, bacterial infections and mycoses, neoplasms, digestive system, digestive system diseases
Abstract

Additional file 4: Appendix Text 1: Associations between explored psychiatric symptoms.

Published
2021
Full Text
View/download PDF

24. Additional file 1 of Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms

Author

Bigseth, Therese Torgersen, Engh, John Abel, Egeland, Jens, Andersen, Eivind, Andreassen, Ole Andreas, Bang-Kittilsen, Gry, Falk, Ragnhild Sørum, Holmen, Tom Langerud, Lindberg, Morten, Mordal, Jon, Nielsen, Jimmi, Steen, Nils Eiel, Ueland, Thor, Vang, Torkel, and Fredriksen, Mats

Subjects
mental disorders, behavioral disciplines and activities
Abstract

Additional file 1: Table A Sensitivity analysis: Associations between depressive symptoms and suPAR, multivariable regression analyses in participants with schizophrenia.

Published
2021
Full Text
View/download PDF

25. Additional file 5 of Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms

Author

Bigseth, Therese Torgersen, Engh, John Abel, Egeland, Jens, Andersen, Eivind, Andreassen, Ole Andreas, Bang-Kittilsen, Gry, Falk, Ragnhild Sørum, Holmen, Tom Langerud, Lindberg, Morten, Mordal, Jon, Nielsen, Jimmi, Steen, Nils Eiel, Ueland, Thor, Vang, Torkel, and Fredriksen, Mats

Abstract

Additional file 5: Appendix Text 2 - Exploration of the relationship between hsCRP and depressive symptoms beyond CDSS sum score.

Published
2021
Full Text
View/download PDF

26. Additional file 3 of Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms

Author

Bigseth, Therese Torgersen, Engh, John Abel, Egeland, Jens, Andersen, Eivind, Andreassen, Ole Andreas, Bang-Kittilsen, Gry, Falk, Ragnhild Sørum, Holmen, Tom Langerud, Lindberg, Morten, Mordal, Jon, Nielsen, Jimmi, Steen, Nils Eiel, Ueland, Thor, Vang, Torkel, and Fredriksen, Mats

Abstract

Additional file 3:. Metabolic risk associated with antipsychotic medication.

Published
2021
Full Text
View/download PDF

27. Additional file 2 of Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms

Author

Bigseth, Therese Torgersen, Engh, John Abel, Egeland, Jens, Andersen, Eivind, Andreassen, Ole Andreas, Bang-Kittilsen, Gry, Falk, Ragnhild Sørum, Holmen, Tom Langerud, Lindberg, Morten, Mordal, Jon, Nielsen, Jimmi, Steen, Nils Eiel, Ueland, Thor, Vang, Torkel, and Fredriksen, Mats

Subjects
health care facilities, manpower, and services, mental disorders, education, behavioral disciplines and activities, health care economics and organizations
Abstract

Additional file 2: Table B1 Internal reliability of the Norwegian version of the Calgary Depression Scale for Schizophrenia. Table B2 Internal reliability of the Norwegian version of the Calgary Depression Scale for Schizophrenia, by sex.

Published
2021
Full Text
View/download PDF

28. Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia:a sex-dependent association with depressive symptoms

Author

Bigseth, Therese Torgersen, Engh, John Abel, Egeland, Jens, Andersen, Eivind, Andreassen, Ole Andreas, Bang-Kittilsen, Gry, Falk, Ragnhild Sørum, Holmen, Tom Langerud, Lindberg, Morten, Mordal, Jon, Nielsen, Jimmi, Steen, Nils Eiel, Ueland, Thor, Vang, Torkel, Fredriksen, Mats, Bigseth, Therese Torgersen, Engh, John Abel, Egeland, Jens, Andersen, Eivind, Andreassen, Ole Andreas, Bang-Kittilsen, Gry, Falk, Ragnhild Sørum, Holmen, Tom Langerud, Lindberg, Morten, Mordal, Jon, Nielsen, Jimmi, Steen, Nils Eiel, Ueland, Thor, Vang, Torkel, and Fredriksen, Mats

Abstract

Background: There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. Method: In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. Results: Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. Conclusion: Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.

Published
2021

29. Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side-effects : a randomized, double-blinded crossover trial

Author

Kristiansen, Oscar, Vethe, Nils Tore, Peersen, Kari, Fagerland, Morten Wang, Sverre, Elise, Jensen, Elena Prunés, Lindberg, Morten, Gjertsen, Erik, Gullestad, Lars, Perk, Joep, Dammen, Toril, Bergan, Stein, Husebye, Einar, Otterstad, Jan Erik, Munkhaugen, John, Kristiansen, Oscar, Vethe, Nils Tore, Peersen, Kari, Fagerland, Morten Wang, Sverre, Elise, Jensen, Elena Prunés, Lindberg, Morten, Gjertsen, Erik, Gullestad, Lars, Perk, Joep, Dammen, Toril, Bergan, Stein, Husebye, Einar, Otterstad, Jan Erik, and Munkhaugen, John

Abstract

AIMS: To estimate the effect of atorvastatin on muscle symptom intensity in coronary heart disease (CHD) patients with self-perceived statin-associated muscle symptoms (SAMS) and to determine the relationship to blood levels of atorvastatin and/or metabolites. METHODS AND RESULTS: A randomized multi-center trial consecutively identified 982 patients with previous or ongoing atorvastatin treatment after a CHD event. Of these, 97 (9.9%) reported SAMS and 77 were randomized to 7-weeks double-blinded treatment with atorvastatin 40 mg/day and placebo in a crossover design. The primary outcome was the individual mean difference in muscle symptom intensity between the treatment periods, measured by visual-analogue scale (VAS) scores. Atorvastatin did not affect the intensity of muscle symptoms among 71 patients who completed the trial. Mean VAS difference [statin-placebo] was 0.31 (95% CI -0.24-0.86). The proportion with more muscle symptoms during placebo than atorvastatin was 17% (n = 12), 55% (n = 39) had the same muscle symptom intensity during both treatment periods whereas 28% (n = 20) had more symptoms during atorvastatin than placebo (confirmed SAMS). There were no differences in clinical or pharmacogenetic characteristics between these groups. The levels of atorvastatin and/or metabolites did not correlate to muscle symptom intensity among patients with confirmed SAMS (Spearmans rho ≤0.40, for all variables). CONCLUSION: Re-challenge with high-intensity atorvastatin did not affect the intensity of muscle symptoms in CHD patients with self-perceived SAMS during previous atorvastatin therapy. There was no relationship between muscle symptoms and the systemic exposure to atorvastatin and/or its metabolites. The findings encourage an informed discussion to elucidate other causes of muscle complaints and continued statin use.

Published
2021
Full Text
View/download PDF

31. Bone mineral density and bone turnover after sleeve gastrectomy and gastric bypass, a randomized controlled trial

Author

Hofsø, Dag, Hillestad, Thor Olav Widerøe, Halvorsen, Erling, Fatima, Farhat, Johnson, Line Kristin, Lindberg, Morten, Svanevik, Marius, Sandbu, Rune, and Hjelmesæth, Jøran

Subjects
musculoskeletal diseases, nutritional and metabolic diseases
Abstract

Context Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), is associated with increased risk of osteoporotic fractures. It is unknown whether RYGB or sleeve gastrectomy (SG) have different effects on bone health. Objective To compare changes in bone mineral density and markers of bone turnover one year after SG and RYGB. Design, Setting, Patients, and Interventions Randomized, triple-blind, single-center trial at a tertiary care center in Norway. Primary outcome was diabetes remission. Patients with severe obesity and type 2 diabetes were randomized and allocated (1:1) to SG or RYGB. Main Outcome Measures Changes in areal bone mineral density (aBMD) and bone turnover markers. Results Femoral neck, total hip, and lumbar spine aBMD, but not total body aBMD, decreased significantly more after RYGB (n=44) than after SG (n=48) [mean (95% CI) between group differences -2.8 % (-0.8 to -4.7), -3.0 % (-0.9 to -5.0), -4.2 % (-2.1 to -6.4), and -0.5 % (0.6 to -1.6), respectively]. The increase in procollagen type 1 N-terminal propeptide (P1NP) and C-telopeptide of type I collagen (CTX-1) were approximately 100% higher after RYGB than after SG, (both time x group, P

Published
2020

37. Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial

Author

Kristiansen, Oscar, primary, Vethe, Nils Tore, additional, Peersen, Kari, additional, Wang Fagerland, Morten, additional, Sverre, Elise, additional, Prunés Jensen, Elena, additional, Lindberg, Morten, additional, Gjertsen, Erik, additional, Gullestad, Lars, additional, Perk, Joep, additional, Dammen, Toril, additional, Bergan, Stein, additional, Husebye, Einar, additional, Otterstad, Jan Erik, additional, and Munkhaugen, John, additional

Published
2020
Full Text
View/download PDF

43. Single-centre, triple-blinded, randomised, 1-year, parallel-group, superiority study to compare the effects of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function in subjects with morbid obesity: a protocol for the Obesitysurgery in Tønsberg(Oseberg) study

Author

Borgeraas, Heidi, primary, Hjelmesæth, Jøran, additional, Birkeland, Kåre Inge, additional, Fatima, Farhat, additional, Grimnes, John Olav, additional, Gulseth, Hanne L, additional, Halvorsen, Erling, additional, Hertel, Jens Kristoffer, additional, Hillestad, Tor Olav Widerøe, additional, Johnson, Line Kristin, additional, Karlsen, Tor-Ivar, additional, Kolotkin, Ronette L, additional, Kvan, Nils Petter, additional, Lindberg, Morten, additional, Lorentzen, Jolanta, additional, Nordstrand, Njord, additional, Sandbu, Rune, additional, Seeberg, Kathrine Aagelen, additional, Seip, Birgitte, additional, Svanevik, Marius, additional, Valderhaug, Tone Gretland, additional, and Hofsø, Dag, additional

Published
2019
Full Text
View/download PDF

45. Falsely markedly elevated 25-hydroxyvitamin D in patients with monoclonal gammopathies.

Author

Hager, Helle Borgstrøm, Bolstad, Nils, Warren, David J., Ness, Marianne Vindal, Seierstad, Birgitte, and Lindberg, Morten

Subjects
MONOCLONAL gammopathies, LIQUID chromatography-mass spectrometry, VITAMIN D, RHEUMATOID factor, MONOCLONAL antibodies, DILUTION
Abstract

Monoclonal immunoglobulins can cause interference in many laboratory analyses. During a 4 month period we observed seven patients with monoclonal disease and falsely extremely elevated 25-hydroxyvitamin D (25(OH)D) results above 160 ng/mL (>400 nmol/L) measured using an immunoassay from Abbott Diagnostics. Based on these findings, we studied the occurrence of falsely elevated 25(OH)D in samples with paraproteins and investigated possible mechanisms of the observed interference. 25(OH)D was analyzed using the Architect i2000 platform from Abbott Diagnostics and a higher order method, liquid chromatography-mass spectrometry (LC-MS/MS), in serum samples from 50 patients with known monoclonal disease. Patients with falsely elevated 25(OH)D were included in further studies to elucidate the cause of interference. Spuriously elevated results were in addition analyzed on two alternative platforms (Siemens and Roche). Falsely elevated 25(OH)D levels were present in eight patients on the Abbott analyzer and one on the Siemens platform. Results from Roche were comparable with LC-MS/MS. Additional investigations excluded elevated concentrations of rheumatoid factor and heterophilic antibodies as the cause of interference in the Abbott assay. Laboratories should be aware of the risk of falsely elevated 25(OH)D in samples run on the Architect analyzer from patients with monoclonal disease. Highly elevated vitamin D results should be diluted and if the dilution is non-linear, rerun by a different method, preferably LC-MS/MS. In patients with spuriously elevated 25(OH)D without known monoclonal disease, the laboratory should consider requesting protein electrophoresis to exclude paraprotein interference. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. Bone Mineral Density and Turnover After Sleeve Gastrectomy and Gastric Bypass: A Randomized Controlled Trial (Oseberg).

Author

Hofsø, Dag, Widerøe Hillestad, Thor Olav, Halvorsen, Erling, Fatima, Farhat, Johnson, Line Kristin, Lindberg, Morten, Svanevik, Marius, Sandbu, Rune, and Hjelmesæth, Jøran

Subjects
BONE density, CALCIUM metabolism, GASTRIC bypass, CALCIUM supplements, RANDOMIZED controlled trials, SLEEVE gastrectomy, FEMUR neck, BODY composition
Published
2021
Full Text
View/download PDF

47. Reference values for osmolal gap in healthy subjects and in medical inpatients.

Author

Skaaland, Helene, Larstorp, Anne Cecilie K., Lindberg, Morten, and Jacobsen, Dag

Subjects
METHANOL, MORTALITY, OSMOLAR concentration, ROUTINE diagnostic tests, ETHYLENE glycol, BLOOD donors, REFERENCE values, HUMAN research subjects, RETROSPECTIVE studies, ALCOHOLS (Chemical class)
Abstract

Methanol and ethylene glycol poisonings are associated with high morbidity and mortality rates if treatment is not initiated early. Since few hospitals measure these toxic alcohols on a 24/7 basis, calculation of the osmolal gap (OG) is an important diagnostic tool. The reference value for the OG lacks consensus. We, therefore, wanted to update the reference value for OG in presumed healthy subjects and study OG values in internal medicine patients. The OG was calculated in 285 patients at the Medical Clinic at Oslo University Hospital, and in 118 healthy blood donors at Vestfold Hospital Trust. OG was calculated by the formula: OG = Measured osmolality - calculated osmolality ((1.86 × s-sodium + s-glucose + s-urea)/0.93) mOsm/kg H2O. In the patients, median OG was 0 mOsm/kg H2O (interquartile range -3 to 3 mOsm/kg H2O, range -16 to103 mOsm/kg H2O). When corrected for one outlier, the central 95% interval for OG was -10 to 20. The healthy blood donors had a median OG of -1 mOsm/kg H2O (interquartile range -3 to1 mOsm/kg H2O, range -13 to 8 mOsm/kg H2O). When corrected for outliers, the reference range was -6 to 5 mOsm/kg H2O. Based on results from a healthy population, we suggest a reference value for the OG of ≤5 mOsm/kg H2O, but also recommend, based on our results from medical inpatients, to keep today's practice for suspecting poisoning with toxic alcohols at an elevated OG of ≥20 mOsm/kg H2O. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

49. Single-centre, triple-blinded, randomised, 1-year, parallel-group, superiority study to compare the effects of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function in subjects with morbid obesity: a protocol for the Obesity surgery in Tønsberg (Oseberg) study

Author

Borgeraas, Heidi, Hjelmesæth, Jøran, Birkeland, Kåre Inge, Fatima, Farhat, Grimnes, John Olav, Gulseth, Hanne L., Halvorsen, Erling, Hertel, Jens Kristoffer, Widerøe Hillestad, Tor Olav, Johnson, Line Kristin, Karlsen, Tor-Ivar, Kolotkin, Ronette L., Kvan, Nils Petter, Lindberg, Morten, Lorentzen, Jolanta, Nordstrand, Njord, Sandbu, Rune, Seeberg, Kathrine Aagelen, Seip, Birgitte, and Svanevik, Marius

Abstract

Introduction Bariatric surgery is increasingly recognised as an effective treatment option for subjects with type 2 diabetes and obesity; however, there is no conclusive evidence on the superiority of Roux-en-Y gastric bypass or sleeve gastrectomy. The Oseberg study was designed to compare the effects of gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function. Methods and analysis Single-centre, randomised, tripleblinded, two-armed superiority trial carried out at the Morbid Obesity Centre at Vestfold Hospital Trust in Norway. Eligible patients with type 2 diabetes and obesity were randomly allocated in a 1:1 ratio to either gastric bypass or sleeve gastrectomy. The primary outcome measures are (1) the proportion of participants with complete remission of type 2 diabetes (HbA1c≤6.0% in the absence of blood glucose-lowering pharmacologic therapy) and (2) β-cell function expressed by the disposition index (calculated using the frequently sampled intravenous glucose tolerance test with minimal model analysis) 1 year after surgery. Ethics and dissemination The protocol of the current study was reviewed and approved by the regional ethics committee on 12 September 2012 (ref: 2012/1427/REK sør-øst B). The results will be disseminated to academic and health professional audiences and the public via publications in international peer-reviewed journals and conferences. Participants will receive a summary of the main findings. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results